Abstract
Cancer-associated autoantibodies show promise as sensitive biomarkers for the early detection of cancer. To test the immunogenicity of chromogranin A (ChgA) as a B cell autoantigen and to assess the potential applications of ChgA autoantibodies as novel biomarkers for the diagnosis of non-small cell lung cancer (NSCLC), we developed a high-content peptide microarray using ChgA peptides. Autoantibody profiling was carried out using sera from 168 individuals with NSCLC and 97 healthy controls. We present evidence for the occurrence of autoantibodies to ChgA peptides in patient sera and identified five highly responsive peptides in the NSCLC group using significance analysis of microarray (SAM). Receiver operating characteristic analyses showed that ChgA autoantibodies are valuable in the predictive diagnosis of NSCLC, suggesting that serum autoantibodies to ChgA-derived peptides are promising novel markers of NSCLC. Moreover, the high-content peptide microarray antibody profiling reported in this work provides a powerful tool to visualize the overall B cell response to ChgA peptides and should enable the rapid development of in-depth research into ChgA.
Similar content being viewed by others
References
Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, et al. GLOBOCAN 2012: estimated cancer incidence, mortality and prevalence worldwide in 2012. 2014.
Berendsen HH, De Leij L, Poppema S, Postmus PE, Boes A, Sluiter HJ. Clinical characterization of non-small-cell lung cancer tumors showing neuroendocrine differentiation features. Journal of Clinical Oncology. 1989;7(11):1614–20.
Graziano SL, Mazid R, Newman N, Tatum A, Oler A, Mortimer JA, et al. The use of neuroendocrine immunoperoxidase markers to predict chemotherapy response in patients with non-small-cell lung cancer. Journal of Clinical Oncology. 1989;7(10):1398–406.
Howe M, Chapman A, Kerr K, Dougal M, Anderson H, Hasleton PS. Neuroendocrine differentiation in non‐small cell lung cancer and its relation to prognosis and therapy. Histopathology. 2005;46(2):195–201.
Chiari M, Cretich M, Corti A, Damin F, Pirri G, Longhi R. Peptide microarrays for the characterization of antigenic regions of human chromogranin A. Proteomics. 2005;5(14):3600–3.
O'connor D, Frigon R. Chromogranin A, the major catecholamine storage vesicle soluble protein. Multiple size forms, subcellular storage, and regional distribution in chromaffin and nervous tissue elucidated by radioimmunoassay. Journal of Biological Chemistry. 1984;259(5):3237–47.
Sobol RE, Memoli V, Deftos LJ. Hormone-negative, chromogranin A-positive endocrine tumors. The New England Journal of Medicine. 1989;320(7):444–7.
Nisman B, Heching N, Biran H, Barak V, Peretz T. The prognostic significance of circulating neuroendocrine markers chromogranin a, pro-gastrin-releasing peptide and neuron-specific enolase in patients with advanced non-small-cell lung cancer. Tumor Biology. 2006;27(1):8–16.
Modlin IM, Gustafsson BI, Moss SF, Pavel M, Tsolakis AV, Kidd M. Chromogranin A—biological function and clinical utility in neuroendocrine tumor disease. Annals of Surgical Oncology. 2010;17(9):2427–43.
Stadinski BD, Delong T, Reisdorph N, Reisdorph R, Powell RL, Armstrong M, et al. Chromogranin A is an autoantigen in type 1 diabetes. Nature Immunology. 2010;11(3):225–31.
Gottlieb PA, Delong T, Baker RL, Fitzgerald-Miller L, Wagner R, Cook G, et al. Chromogranin A is a T cell antigen in human type 1 diabetes. Journal of Autoimmunity. 2014;50:38–41.
Tan HT, Low J, Lim SG, Chung M. Serum autoantibodies as biomarkers for early cancer detection. FEBS Journal. 2009;276(23):6880–904.
Leidinger P, Keller A, Ludwig N, Rheinheimer S, Hamacher J, Huwer H, et al. Toward an early diagnosis of lung cancer: an autoantibody signature for squamous cell lung carcinoma. International Journal of Cancer. 2008;123(7):1631–6.
Wu L, Chang W, Zhao J, Yu Y, Tan X, Su T, et al. Development of autoantibody signatures as novel diagnostic biomarkers of non-small cell lung cancer. Clinical Cancer Research. 2010;16(14):3760–8.
Chapman CJ, Healey GF, Murray A, Boyle P, Robertson C, Peek LJ, et al. EarlyCDT®-Lung test: improved clinical utility through additional autoantibody assays. Tumor Biology. 2012;33(5):1319–26.
Lu H, Goodell V, Disis ML. Humoral immunity directed against tumor-associated antigens as potential biomarkers for the early diagnosis of cancer. Journal of proteome research. 2008;7(4):1388–94.
Ma H, Wu Y, Yang X, Liu X, He J, Fu L, et al. Integrated poly (dimethysiloxane) with an intrinsic nonfouling property approaching “absolute” zero background in immunoassays. Analytical chemistry. 2010;82(15):6338–42.
Larsen J, Lund O, Nielsen M. Improved method for predicting linear B-cell epitopes. Immunome Res. 2006;2(2):1–7.
Hecker M, Lorenz P, Steinbeck F, Hong L, Riemekasten G, Li Y, et al. Computational analysis of high-density peptide microarray data with application from systemic sclerosis to multiple sclerosis. Autoimmunity reviews. 2012;11(3):180–90.
Corti A. Chromogranin A, and the tumor microenvironment. Cellular and molecular neurobiology. 2010;30(8):1163–70.
Lu L, Wang YN, Li MC, Wang HB, Pu LJ, Niu WQ, et al. Reduced serum levels of vasostatin-2, an anti-inflammatory peptide derived from chromogranin A, are associated with the presence and severity of coronary artery disease. European Heart Journal. 2012;33(18):2297–306.
Nikoopour E, Cheung R, Bellemore S, Krougly O, Lee‐Chan E, Stridsberg M, et al. Vasostatin‐1 antigenic epitope mapping for induction of cellular and humoral immune responses to chromogranin A autoantigen in NOD mice. European journal of immunology. 2014;44(4):1170–80.
Acknowledgments
This project was partially supported by: CAS Fund (KJZD-EW-J01) and JS Grants (BK20130008, BY2011180) to H.M., Jiangsu Planned Projects for Postdoctoral Research Funds (1401068C) to Y.X., and Science and Technology Planned Projects of Suzhou (SYS201329) to M.J.
Author information
Authors and Affiliations
Corresponding authors
Additional information
Songnan Qi and Mo Huang contributed equally to this work.
Electronic supplementary material
Below is the link to the electronic supplementary material.
ESM 1
Supplemental Table 1. Sequence information of the 40 peptides of ChgA. (DOC 75 kb)
Rights and permissions
About this article
Cite this article
Qi, S., Huang, M., Teng, H. et al. Autoantibodies to chromogranin A are potential diagnostic biomarkers for non-small cell lung cancer. Tumor Biol. 36, 9979–9985 (2015). https://doi.org/10.1007/s13277-015-3794-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13277-015-3794-3